The report also covers products from therapy areas such as Oncology, Toxicology, and Infectious Disease which include the indications Solid Tumor, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Chemotherapy Induced Myelosuppression, Chemotherapy-Induced Diarrhea (CID), Human Immunodeficiency Virus (HIV) Infections (AIDS), and Epstein–Barr Virus (HHV-4) Infections. It also reviews key players involved in Cyclin Dependent Kinase 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Cyclin Dependent Kinase 4 pipeline targets constitutes close to 65 molecules. Out of which, approximately 62 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 13, 19, 22, 1, 10, 27, and 9 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Cyclin Dependent Kinase 4 overview
Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.
For a complete picture of Cyclin Dependent Kinase 4’s drug pipeline, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.